ANI Pharmaceuticals, Inc.
ANIPNASDAQHealthcare● Active
$81.15
+$0.04(+0.05%)
Market Cap$1.8B
P/E Ratio—
52W High$99.5
52W Low$59.61
ANI Pharmaceuticals, Inc. (ANIP) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ANIP · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.88B | $0.61B | $0.49B | $0.32B | $0.22B |
| Cost of Revenue | $0.43B | $0.25B | $0.18B | $0.14B | $0.10B |
| Gross Profit | $0.45B | $0.36B | $0.31B | $0.18B | $0.12B |
| Gross Margin %(computed) | 51.01% | 59.27% | 62.71% | 56.13% | 53.45% |
| Operating Expenses | |||||
| R&D Expenses | $0.05B | $0.04B | $0.03B | $0.02B | $0.01B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.37B | $0.36B | $0.26B | $0.21B | $0.16B |
| Operating Income | $0.08B | $0.00B | $0.05B | ($0.04B) | ($0.04B) |
| Operating Margin %(computed) | 9.20% | 0.10% | 9.65% | -11.15% | -18.41% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.02B | $0.02B | $0.03B | $0.03B | $0.01B |
| Income Before Tax | $0.10B | ($0.02B) | $0.02B | ($0.06B) | ($0.06B) |
| Income Tax Expense | $0.02B | ($0.00B) | $0.00B | ($0.01B) | ($0.01B) |
| Net Income | $0.08B | ($0.02B) | $0.02B | ($0.05B) | ($0.04B) |
| Net Margin %(computed) | 8.87% | -3.01% | 3.86% | -15.14% | -19.71% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $3.50 | $-1.04 | $0.95 | $-3.05 | $-3.40 |
| Wtd Avg Shares | 0.02B | 0.02B | 0.02B | 0.02B | 0.01B |
| EBITDA | $0.21B | $0.06B | $0.11B | $0.03B | $0.00B |
| EBITDA Margin %(computed) | 23.46% | 10.27% | 21.90% | 7.91% | 1.44% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more ANI Pharmaceuticals, Inc. data
About ANI Pharmaceuticals, Inc. (ANIP) Income Statement
ANI Pharmaceuticals, Inc. (ANIP) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ANIP reported revenue of $0.88B, gross profit of $0.45B (gross margin 51.01%), and net income of $0.08B — a net profit margin of 8.87%.
Frequently asked questions
ANIP · 4 questionsANI Pharmaceuticals, Inc. (ANIP) reported revenue of $0.88B for 2025, up 43.8% year-over-year.
ANIP revenueANIP salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08